ReviewCleveland Clinic journal of medicine2013
Carbapenem-resistant Enterobacteriaceae: a menace to our most vulnerable patients.
Review in Cleveland Clinic journal of medicine, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04202861 (A Randomised Controlled Trial Evaluating a Novel Individualised Treatment Strategy for Carbapenem-Resistant Gram-Negative Bacteria Infections), which is not on this map. Cited by 82 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Randomised Controlled Trial Evaluating a Novel Individualised Treatment Strategy for Carbapenem-Resistant Gram-Negative Bacteria Infections (iACT)
Who cites it
82 citing papers in PubMed.
- Ceftazidime-avibactam Versus Doripenem for the Treatment of Complicated Urinary Tract Infections, Including Acute Pyelonephritis: RECAPTURE, a Phase 3 Randomized Trial Program.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2016Trial
- Efficacy and Safety of Ceftazidime-Avibactam Plus Metronidazole Versus Meropenem in the Treatment of Complicated Intra-abdominal Infection: Results From a Randomized, Controlled, Double-Blind, Phase 3 Program.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2016Trial
- Emerging Trends of Beta-Lactamases in Western Nepal: A Growing Public Health Concern.International journal of microbiology · 2025Article
- Aerobic bacteria study, clinical spectrum, and outcome of patients with community-acquired multidrug-resistant pathogens.Journal of family medicine and primary care · 2024Article
- Navigating Antibacterial Frontiers: A Panoramic Exploration of Antibacterial Landscapes, Resistance Mechanisms, and Emerging Therapeutic Strategies.ACS infectious diseases · 2024Review
- Strategies to Overcome Antimicrobial Resistance in Nosocomial Infections, A Review and Update.Infectious disorders drug targets · 2024Review
- A review of the mechanisms that confer antibiotic resistance in pathotypes ofFrontiers in cellular and infection microbiology · 2024Review
- Rising Drug Resistance Among Gram-Negative Pathogens in Bloodstream Infections: A Multicenter Study in Ulanhot, Inner Mongolia (2017-2021).Medical science monitor : international medical journal of experimental and clinical research · 2023Article
- International Epidemiology of Carbapenemase-Producing Escherichia coli.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2023Article
- Clinical and Genomic Characterization of Carbapenem-ResistantMicroorganisms · 2023Article
- In vitro efficacy of cephamycins against multiple extended-spectrum β-lactamase-producing Klebsiella pneumoniae, Proteus mirabilis, and Enterobacter cloacae isolates from dogs and cats.The Journal of veterinary medical science · 2023Article
- Molecular Characterization of SomeMolecules (Basel, Switzerland) · 2023Article
- Impact of an antibiotic stewardship program on antibiotic utilization, bacterial susceptibilities, and cost of antibiotics.Scientific reports · 2023Article
- Bacteriological spectrum, extended-spectrum β-lactamase production and antimicrobial resistance pattern among patients with bloodstream infection in Addis Ababa.Scientific reports · 2023Article
- Prevalence and Phenotypic and Molecular Characterization of Carbapenemase-Producing Gram-Negative Bacteria in Gabon.The American journal of tropical medicine and hygiene · 2023Article
- Prevalence of carbapenem-resistant and extended-spectrum beta-lactamase-producing Enterobacteriaceae in a teaching hospital in Ghana.PloS one · 2023Article
- Review
- Predicting Risk of Multidrug-Resistant Enterobacterales Infections Among People With HIV.Open forum infectious diseases · 2022Article
- Molecular Characterization of Bacterial Isolates from Soil Samples and Evaluation of their Antibacterial Potential against MDRS.Molecules (Basel, Switzerland) · 2022Article
- Cost-effectiveness of carbapenem-resistant Enterobacteriaceae (CRE) surveillance in Maryland.Infection control and hospital epidemiology · 2022Article
22 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
The emergence of carbapenem-resistant Enterobacteriaceae (CRE) highlights the importance of effective antibiotics to maintain the safety of our health care system. Clinicians will encounter CRE as a cause of difficult-to-treat and often fatal infections in hospitalized patients. We review the mechanisms of carbapenem resistance, the dissemination and clinical impact of these resistant organisms, and challenges to their detection, treatment, and control.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.